Seropositivity for Anti-HCV Core Antigen is Independently Associated With Increased All-Cause, Cardiovascular, and Liver Disease-Related Mortality in Hemodialysis Patients

• Ohsawa Masaki

  Department of Hygiene and Preventive Medicine, Iwate Medical University

• Kato Karen

  Division of Urology, San-ai Hospital

• Tanno Kozo

  Department of Hygiene and Preventive Medicine, Iwate Medical University

• Itai Kazuyoshi

  Department of Hygiene and Preventive Medicine, Iwate Medical University

• Fujishima Yosuke

  Department of Hygiene and Preventive Medicine, Iwate Medical University Department of Urology, Iwate Medical University

• Okayama Akira

  The First Institute of Health Service, Japan Anti-Tuberculosis Association

• Turin Tanvir Chowdhury

  Department of Medicine, University of Calgary

• Onoda Toshiyuki

  Department of Hygiene and Preventive Medicine, Iwate Medical University

• Suzuki Kazuyuki

  Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University

• Nakamura Motoyuki

  Division of Cardiovascular Medicine, Nephrology and Endocrinology, Department of Internal Medicine, Iwate Medical University

• Kawamura Kazuko

  Iwate Health Service Association

• Akiba Takashi

  Division of Blood Purification, Kidney Center, Tokyo Women’s Medical University

• Sakata Kiyomi

  Department of Hygiene and Preventive Medicine, Iwate Medical University

• Fujioka Tomoaki

  Department of Urology, Iwate Medical University

抄録

Background: It is not known whether chronic or past hepatitis C virus (HCV) infection contributes to the high mortality rate in hemodialysis patients.<BR>Methods: This prospective study of 1077 adult hemodialysis patients without hepatitis B virus infection used Poisson regression analysis to estimate crude and sex- and age-adjusted rates (per 1000 patient-years) of all-cause, cardiovascular, infectious disease-related and liver disease-related mortality in patients negative for HCV antibody (group A), patients positive for HCV antibody and negative for anti-HCV core antigen (group B), and patients positive for anti-HCV core antigen (group C). The relative risks (RRs) for each cause of death in group B vs group C as compared with those in group A were also estimated by Poisson regression analysis after multivariate adjustment.<BR>Results: A total of 407 patients died during the 5-year observation period. The sex- and age-adjusted mortality rate was 71.9 in group A, 80.4 in group B, and 156 in group C. The RRs (95% CI) for death in group B vs group C were 1.23 (0.72 to 2.12) vs 1.60 (1.13 to 2.28) for all-cause death, 0.75 (0.28 to 2.02) vs 1.64 (0.98 to 2.73) for cardiovascular death, 1.64 (0.65 to 4.15) vs 1.58 (0.81 to 3.07) for infectious disease-related death, and 15.3 (1.26 to 186) vs 28.8 (3.75 to 221) for liver disease-related death, respectively.<BR>Conclusions: Anti-HCV core antigen seropositivity independently contributes to elevated risks of all-cause and cause-specific death. Chronic HCV infection, but not past HCV infection, is a risk for death among hemodialysis patients.

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ｅｐｉｄｅｍｉｏｌｏｇｙ

  Ｊｏｕｒｎａｌ　ｏｆ　Ｅｐｉｄｅｍｉｏｌｏｇｙ 21 (6), 491-499, 2011

  日本疫学会

キーワード

• hepatitis C virus
• hemodialysis
• mortality
• population-based cohort study

詳細情報

• CRID: 1390282679452643840
• NII論文ID: 10029821019
• NII論文ID: 130001090164
• NII書誌ID: AA10952696
• DOI: 10.2188/jea.je20100187
• ISSN: 13499092
• ISSN: 09175040
• Web Site: https://www.jstage.jst.go.jp/article/jea/21/6/21_JE20100187/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012213618
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可